Mark A. Velleca
2018 - G1 Therapeutics
In 2018, Mark A. Velleca earned a total compensation of $1.9M as Chief Executive Officer and President at G1 Therapeutics, a 159% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $321,875 |
|---|---|
| Option Awards | $1,044,529 |
| Salary | $515,000 |
| Other | $33,250 |
| Total | $1,914,654 |
Velleca received $1M in option awards, accounting for 55% of the total pay in 2018.
Velleca also received $321.9K in non-equity incentive plan, $515K in salary and $33.3K in other compensation.
Rankings
In 2018, Mark A. Velleca's compensation ranked 5,969th out of 14,244 executives tracked by ExecPay. In other words, Velleca earned more than 58.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,969 out of 14,244 | 58th |
Division Manufacturing | 2,271 out of 5,765 | 61st |
Major group Chemicals And Allied Products | 850 out of 2,128 | 60th |
Industry group Drugs | 711 out of 1,817 | 61st |
Industry Pharmaceutical Preparations | 554 out of 1,391 | 60th |
Source: SEC filing on April 30, 2019.
Velleca's colleagues
We found five more compensation records of executives who worked with Mark A. Velleca at G1 Therapeutics in 2018.
News
Black Diamond Therapeutics CEO Mark Velleca receives $2.9M in 2023
April 24, 2024
G1 Therapeutics CEO Mark Velleca's 2020 pay stays at $4M
April 28, 2021
G1 Therapeutics Chief Business Officer Mark Avagliano receives $5.5M in 2019
April 24, 2020
G1 Therapeutics Chief Commercial Officer John Demaree receives $7.5M in 2018
April 30, 2019